Eikon Therapeutics, Inc.
corporate_fare Company Profile
Eikon Therapeutics, Inc. (NASDAQ:EIKN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for EIKN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-14, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for EIKN spans 8-K, 10-Q, 10-K, SCHEDULE 13D.
Recent high-impact activity:
- Eikon Therapeutics Updates Corporate Presentation with New Clinical Data and Milestones
- Eikon Therapeutics Q2 2026: Losses Continue, Material Weakness Unresolved
- Eikon Therapeutics Reports Q2 2026 Results and Clinical Updates
- First Patient Dosed in Pivotal Lung Cancer Trial, Shares Jump 10%
- EIK1001 Phase 2 NSCLC Data Shows 63.1% ORR at ASCO, EIK1003 Also Active
Short Interest & Short Volume
9.26 days to coverFINRA reported short interest of 5,452,560 shares in EIKN as of the September 15, 2026 settlement, a 3.3% increase from the prior period — about 9.3 days to cover at its recent average daily volume. On October 2, 2026, 74.2% of EIKN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.